Gilead Sciences | Kortsiktig Gjeld



Current Liabilities Endring Dato
AbbVie USD 38.75B 4.31B 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Eli Lilly USD 30.07B 1.69B 2025-03
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 20.83B 866M 2025-03
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.89B 244.96M 2025-03
J&J USD 56.9B 6.58B 2025-03
Merck USD 28.42B 1.17B 2024-12
Moderna USD 1.6B 602M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Sanofi 32.22B 3.06B 2025-03
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
United Therapeutics USD 721.5M 16.6M 2025-03
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Gilead Sciences Kortsiktig Gjeld - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.